Q3 FY2026 · ended Sep 26, 2026 · Revenue $982.73M, -2.2% YoY · Filed Nov 4, 2026
Charles River Laboratories International, Inc. (CRL) files with the SEC under industry code 8731, Services-Commercial Physical & Biological Research. In Q3 of fiscal 2026, the quarter ended Sep 26, 2026, it reported revenue of $982.7 million and net income of $333.1 million. Free cash flow was $207.3 million. As of Sep 26, 2026 it held $200.4 million in cash and investments and $417.1 million in total debt.
Company profile
- Industry
- Services-Commercial Physical & Biological Research (SIC 8731)
- Listed as
- CRL (NYSE)
- Fiscal year ends
- December 27
- Headquarters
- Wilmington, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1100682
- Former names
- CHARLES RIVER LABORATORIES INTERNATIONAL INC (until May 30, 2019); CHARLES RIVER LABORATORIES HOLDINGS INC (until Jan 28, 2000)
Other Services-Commercial Physical & Biological Research companies
- Iqvia Holdings Inc. IQV
- Incyte Corp INCY
- Medpace Holdings, Inc. MEDP
- Icon PLC ICLR
- Absci Corp ABSI
- OmniAb, Inc. OABI
- NRC Health NRC
- Maxcyte, Inc. MXCT
All 17 Services-Commercial Physical & Biological Research companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 26, 2026 |
Q2 FY2026 Jun 27, 2026 |
Q1 FY2026 Mar 28, 2026 |
Q4 FY2025 Dec 27, 2025 |
Q3 FY2025 Sep 27, 2025 |
|---|---|---|---|---|---|
| Revenue | $982.7M | $1.0B | $995.8M | $994.2M | $1.0B |
| Operating income | $202.6M | $119.9M | $119.9M | -$283.4M | $133.8M |
| Net income | $333.1M | -$1.5M | -$14.8M | -$276.6M | $54.4M |
| Diluted EPS | $6.86 | -$0.03 | -$0.30 | -$5.68 | $1.10 |
| Operating cash flow | $254.1M | $179.7M | $41.1M | $147.5M | $213.8M |
| Free cash flow | $207.3M | $148.6M | -$14.8M | $58.6M | $178.2M |
| Total assets | $7.5B | $7.5B | $7.7B | $7.1B | $7.5B |
| Total liabilities | $4.2B | $4.6B | $4.7B | $3.9B | $4.1B |
| Stockholders' equity | $3.2B | $2.8B | $2.9B | $3.2B | $3.4B |
| Cash and investments | $200.4M | $192.0M | $191.8M | $213.8M | $207.1M |
| Total debt | $417.1M | $423.0M | $410.4M | $519.8M | $471.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 26, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 24, 2026 | Sep 24, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 27, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
May 11, 2026 | May 5, 2026 |
All 1005 Charles River Laboratories International, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.